Announcements Trials
Browse Landscape

Phase

Phase 3 1

Status

Active not recruiting 1

Sponsor Class

NIH 1

Study Type

Interventional 1

Sponsor

Cancer Type

Plasma cell 1

Conditions

Leukemia, Myeloid, Acute 6Precursor Cell Lymphoblastic Leukemia-Lymphoma 5Myelodysplastic Syndromes 4Burkitt Lymphoma 4Multiple Myeloma 2Lymphoma, Large-Cell, Anaplastic 2Leukemia, Myelomonocytic, Chronic 2Leukemia, Biphenotypic, Acute 2Ganglioneuroblastoma 2Smoldering Multiple Myeloma 1Precursor T-Cell Lymphoblastic Leukemia-Lymphoma 1Neuroblastoma 1Myeloproliferative Disorders 1Lymphoma, T-Cell 1Lymphoma, Mantle-Cell 1Lymphoma, Large B-Cell, Diffuse 1Lymphoma, Follicular 1Lymphoma, B-Cell, Marginal Zone 1Leukemia, Prolymphocytic 1Leukemia, Plasma Cell 1Leukemia, Myelogenous, Chronic, BCR-ABL Positive 1Leukemia, Lymphocytic, Chronic, B-Cell 1Hodgkin Disease 1

Interventions

dexamethasone acetate 2dexamethasone 21-phosphate 2auricularum 2Lenalidomide 2Dexamethasone 2Calcium Dobesilate 2iberdomide 1daratumumab 1Stem Cell Transplantation 1Peripheral Blood Stem Cell Transplantation 1Melphalan 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Smoldering Multiple Myeloma × Stem Cell Transplantation × 30 days × Clear all
NCT00114101 2026-05-29

Lenalidomide in Treating Patients With Multiple Myeloma Undergoing Autologous Stem Cell Transplant

National Cancer Institute (NCI)

Phase 3 Active not recruiting
460 enrolled 11 charts
Plasma cell

Smoldering Multiple Myeloma, Multiple Myeloma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡